重组海蚯蚓纤溶酶的克隆、表达及活性鉴定北大核心CSCD

纤溶酶在溶栓治疗中起重要作用,能够溶解血凝块的主要成分纤维蛋白。采用RACE方法从海蚯蚓消化道组织中扩增出海蚯蚓纤溶酶编码序列,构建该基因原核表达载体,并进一步构建工程菌表达融合蛋白,经Ni2+树脂柱纯化后通过平板法检测该融合蛋白纤维蛋白酶原激活活性。结果获得海蚯蚓纤溶酶的c DNA序列和氨基酸序列,并成功构建重组表达载体p ET-21a-AFE,表达纯化出融合蛋白,该融合蛋白能够激活纤维蛋白酶原而溶解纤维蛋白。总之,本研究获得了海蚯蚓纤溶酶的c DNA序列和氨基酸序列,并初步证明其具有纤维蛋白酶原激活活性,为临床新型溶栓药物的开发提供实验基础。     

重组海蚯蚓纤溶酶的克隆、表达及活性鉴定

纤溶酶在溶栓治疗中起重要作用,能够溶解血凝块的主要成分纤维蛋白。采用RACE方法从海蚯蚓消化道组织中扩增出海蚯蚓纤溶酶编码序列,构建该基因原核表达载体,并进一步构建工程菌表达融合蛋白,经Ni2+树脂柱纯化后通过平板法检测该融合蛋白纤维蛋白酶原激活活性。结果获得海蚯蚓纤溶酶的c DNA序列和氨基酸序列,并成功构建重组表达载体p ET-21a-AFE,表达纯化出融合蛋白,该融合蛋白能够激活纤维蛋白酶原而溶解纤维蛋白。总之,本研究获得了海蚯蚓纤溶酶的c DNA序列和氨基酸序列,并初步证明其具有纤维蛋白酶原激活活性,为临床新型溶栓药物的开发提供实验基础。     

汉滩病毒M、S基因不同拼接方式在昆虫细胞中融合表达效果比较

将汉滩病毒囊膜糖蛋白G1与核蛋白 (NP)部分片段以不同方式拼接 ,构建G1S0 .7或S0 .7G1嵌合基因 ,分别插入杆状病毒表达载体 pFBD ,转化DH10Bac致敏菌 ,获得含有嵌合基因的重组穿梭质粒Bacmid ,用其转染Sf9细胞 ,快速筛选出含有G1S0 .7或S0 .7G1嵌合基因的重组杆状病毒 ,在昆虫细胞中表达外源融合蛋白。利用间接免疫荧光、ELISA和免疫印迹对表达产物进行检测。结果表明 ,含G1S0 .7嵌合基因之重组杆状病毒可在昆虫细胞中表达出融合蛋白 ,该蛋白可被抗汉滩病毒核蛋白及糖蛋白G1特异性单抗所识别 ,其分子量约 97kD ;含S0 .7G1嵌合基因之重组杆状病毒在昆虫细胞中表达的融合蛋白 ,只能被抗汉滩病毒核蛋白特异性单抗所识别 ,其分子量约 4 3kD。上述结果提示 ,G1S0 .7嵌合基因可能在昆虫细胞中表达出完整的具有生物学活性的融合蛋白 ,S0 .7G1嵌和基因的昆虫细胞表达产物不完整 ,且生物学活性不如G1S0 .7嵌合基因的表达产物     

基于流式细胞术分选的高效表达外源基因细胞的筛选

目的：以增强型绿色荧光蛋白（EGFP）作为报告基因,用流式细胞术筛选高表达EGFP的细胞,从而获得外源基因高效表达细胞株。方法：构建在EGFPC端编码区融合新霉素（neomycin）抗性基因的融合基因EGFP-Neomycin,将其插入pcDNA3.1（＋）载体,构建EGFP-Neomycin融合基因表达载体pcDNAEN,转染CHO-K1细胞,G418加压筛选和倒置荧光显微镜观察证实所表达的EGFP-Neomycin融合蛋白具有新霉素抗性和激发EGFP荧光双功能;将编码组织型纤溶酶原激活剂（tPA）的cDNA插入pcDNAEN中CMV启动子下游,构建表达tPA的表达载体pcDNAEN/tPA。结果：流式细胞术分析和tPA纤维蛋白溶解活性测定表明,pcDNAEN/tPA转染CHO-K1细胞的EGFP相对荧光强度（RFT）的自然对数值与tPA表达水平呈明显的直线相关关系,相关系数为0.983;比较部分未经流式细胞仪分选的pcDNAEN/tPA转染阳性细胞克隆和RFT分布在100～1000的pcDNAEN/tPA转染阳性细胞克隆的tPA表达水平,经流式细胞术分选获得的细胞克隆的tPA平均表达水平和最高表达水平分别是未经分选获得的细胞克隆的3.9倍和4.1倍。结论：构建的EGFP-Neomycin融合基因具有双功能,建立了利用流式细胞术筛选外源基因高效表达物细胞株的方法。     

Mpl与绿色荧光蛋白融合基因的真核载体构建及表达

目的:探索Mpl与绿色荧光蛋白GFP基因共同转粢哺乳动物细胞NIH3T3的方法.方法:采用PCR方法将GFP基因与Mpl基因构建融合荧光蛋白的真核表达载体,用脂质体介导转染NIH3T3细胞和筛选稳定细胞系,使用荧光显微镜方法和Westernblotting检测转染效果.结果:利用PCR方法有效扩增了Mpl基因,构建了融合荧光蛋白的真核表达载体,序列分析表明所构建的含Mpl基因的质粒与设计相同,使用荧光显微镜方法和Western blotting检测Mpl融合绿色荧光蛋白表达载体成功转染NIH3T3细胞.结论:成功构建了Mpl荧光表达载体,融合基因可以在NIH3T3细胞中稳定表达,为进一步研究Mpl的生物学活性及其与hNUDC蛋白相互作用提供了重要的理论依据.     

腺病毒载体介导的重组蛋白sTNFRII-gAD快速表达和制备

利用腺病毒载体高效感染哺乳动物细胞及表达外源基因的特性,建立一种快速高效表达及制备重组蛋白的方法,并用该方法获得sTNFRII-gAD (可溶性肿瘤坏死因子受体II-脂联素球部融合蛋白) 蛋白纯品。首先用携带EGFP基因的腺病毒载体rAd5-EGFP以不同的腺病毒用量 (MOI) (0~1 000) 感染BHK21c022细胞,观察比较其转导效率和细胞毒性。用AdMax腺病毒载体系统制备携带融合基因sTNFRII-gAD的重组复制缺陷型5型腺病毒rAd5-sTNFRII-gAD。用rAd5-sTNFRII-gAD以不同的MOI (0~1 000) 感染BHK21c022细胞,收取上清进行Western blotting分析,比较上清中sTNFRII-gAD蛋白的表达量。在此基础上,用rAd5-sTNFRII-gAD以MOI 100感染大量培养的BHK21c022细胞,在无血清培养条件下反复多次收取培养上清,经过硫酸铵浓缩、分子筛柱层析、透析等步骤浓缩和纯化sTNFRII-gAD融合蛋白,并体外测定该融合蛋白拮抗TNFa的活性。结果获得了携带sTNFRII-gAD融合基因的重组腺病毒rAd5-sTNFRII-gAD;用rAd5-EGFP感染BHK21c022细胞结果表明,随着腺病毒用量的增高,表达EGFP蛋白的BHK21c022细胞数量和亮度明显增加;MOI在0~100之间被感染的BHK21c022细胞未表现出明显的细胞毒性,MOI为1 000时可观察到细胞变圆和少量死亡现象。Western blotting分析结果表明,随着腺病毒用量的增高,培养上清中sTNFRII-gAD融合蛋白表达量明显增加,以MOI为1 000时最高。在此基础上,我们用MOI为100的rAd5-sTNFRII-gAD感染5个转瓶培养的BHK21c022细胞以制备sTNFRII-gAD融合蛋白。每个转瓶加无血清培养液100 mL,每48 h收获上清1次并换液,反复6次收取培养上清共约3 L,经过纯化获得了约11 mg的sTNFRII-gAD融合蛋白。体外活性测定实验表明,获得的sTNFRII-gAD融合蛋白能有效拮抗TNFα对L929细胞的杀伤作用。腺病毒载体/BHK21细胞表达系统是一个简便、高效、通用的表达系统,利用该系统成功制备了有生物学活性的sTNFRII-gAD融合蛋白。该表达系统的特点是生产规模易于放大,适应无血清培养,可以反复多次收获目标蛋白。     

中介蝮蛇毒纤溶酶基因真核表达载体的构建及其功能的研究

目的:蛇毒纤维蛋白溶解酶能直接溶解纤维蛋白或纤维蛋白原,在心脑血管疾病的治疗方面具有潜在的应用价值。方法:采用双酶切技术从pMD18T-FLE I克隆载体上获得中介蝮蛇毒纤溶酶基因编码区,再将其亚克隆到真核表达载体pFASTBACHTa上,经转化、筛选和鉴定,获得重组真核表达质粒pFASTBACHTa-FLE。重组质粒经小鼠尾静脉快速注入小鼠体内,进行瞬时表达。结果:经SDS-PAGE和Western blot检测,表明在小鼠肝脏组织中有重组FLE蛋白表达。免疫组织化学检测证明该蛋白在小鼠肝脏组织中大量表达。纤维蛋白平板法鉴定该重组蛋白具有较高的纤溶活性,其活性呈现出剂量相关性和时间依赖性。因此为进一步对中介蝮蛇毒纤溶酶的应用奠定了坚实的基础。     

拟南芥血红蛋白1的亚细胞定位

为研究拟南芥的血红蛋白1(AtGLB1)基因的亚细胞定位,该实验构建了拟南芥血红蛋白1基因与绿色荧光蛋白基因融合的植物表达载体pUCGFP/ AtGLB1.利用基因枪转化法将重组载体转入洋葱表皮细胞瞬时表达,通过检测融合蛋白在洋葱表皮细胞中的分布来确定拟南芥血红蛋白1在细胞中的定位.荧光显微镜检测结果表明,AtGLB1基因表达产物主要定位在细胞核中,少量定位在细胞质中.     

人胰高血糖素样肽-1与人血清白蛋白融合蛋白在毕赤酵母中的表达

目的：在巴斯德毕赤酵母中表达有降糖活性的人胰高血糖素样肽-1（hGLP-1）突变体（2Gly-hGLP-1）与人血清白蛋白（HSA）的融合蛋白。方法：为将GLP-1氨基酸序列第2位的丙氨酸（Ala）定点突变为甘氨酸（Gly）,根据毕赤酵母偏爱密码子合成编码2Gly-hGLP-1的基因;采用重叠PCR法拼接2Gly-hGLP-1和HSA的基因,使得2Gly-hGLP-1的C端与HSA的N端通过甘氨酸五肽接头连接;将该融合基因插入表达载体pPIC9构建为重组载体pPIC9/2Gly-hGLP-1-HSA,电击转化至毕赤酵母GS115细胞,通过表型筛选和诱导表达实验获得高效表达菌株;工程菌在5L发酵罐中培养后,对发酵产物进行分离纯化和生物学活性分析。结果：融合蛋白在5L发酵罐中的表达量约为200mg/L,经纯化后纯度可达95%以上;小鼠糖耐量实验表明该融合蛋白具有明显的控血糖活性。结论：在毕赤酵母中分泌表达的融合蛋白2Gly-hGLP-1-HSA具有降血糖活性。     

病原诱导的小麦ERF转录因子TaERF1b的原核表达及纯化

为了得到纯化的TaERFlb活性蛋白,将TaERFlb基因含有AP2／ERF结构域的片段插入原核表达载体pGEX-4T-1的多克隆位点中,构建GST-TaERFlb融合蛋白表达载体,并转化到犬肠杆菌BL21（DE3）中。0．1mmol／L1PTG即能诱导融合蛋白表达,37℃诱导4h或30℃诱导8h,融合蛋白均以包涵体的形式表达,16℃诱导12h,融合蛋白不表达。包涵体经溶解及稀释复性后,过GST亲和层析柱,获得纯化的融合蛋白,考马斯亮蓝法测得纯化蛋白的浓度约为0．5ug／ul,凝胶阻滞实验表明包涵体复性成功．所得蛋白具有生物活性：     

Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices

Most growth factors naturally involved in development and regeneration demonstrate strong binding to the extracellular matrix and are retained there until being locally mobilized by cells. In spite of this feedback between cell activity and growth factor mobilization in the extracellular matrix, this approach has not been extensively explored in therapeutic situations. We present an engineered bone morphogenetic protein-2 (BMP-2) fusion protein that mimics such function in a surgically relevant matrix, fibrin, incorporated into the matrix until it is locally liberated by cell surface-associated proteases. A tripartite fusion protein, denoted TG-pl-BMP-2, was designed and produced recombinantly. An N-terminal transglutaminase substrate (TG) domain provides covalent attachment to fibrin during coagulation under the influence of the blood transglutaminase factor XIIIa. A central plasmin substrate (pl) domain provides a cleavage site for local release of the attached growth factor from the fibrin matrix under the influence of cell-activated plasmin. A C-terminal human BMP-2 domain provides osteogenic activity. TG-pl-BMP-2 in fibrin was evaluated in vivo in critical-size craniotomy defects in rats, where it induced 76% more defect healing with bone at 3 weeks with a dose of 1 mug/defect than wildtype BMP-2 in fibrin. After a dosing study in rabbits, the engineered growth factor in fibrin was evaluated in a prospective clinical study for pancarpal fusion in dogs, where it induced statistically faster and more extensive bone bridging than equivalent treatment with cancellous bone autograft. The strong healing response shown by fibrin including a bound BMP-2 variant suggests that with the combination of bound growth factor and ingrowth matrix, it may be possible to improve upon the natural growth factor and even upon tissue autograft.     

重组单链抗体-低分子质量尿激酶融合蛋白在 CHO 细胞中的抗降解研究

抗人纤维蛋白单链抗体-低分子质量尿激酶(Ⅱn-UK)融合蛋白,兼有单链抗体对纤维蛋白的亲和性和尿激酶的溶栓活性,有望开发成为新型导向溶栓药物.但基于通用连接肽(G4S)3的Ⅱn-linker-UK融合蛋白在CHO细胞中表达时出现明显的降解.为了解决此问题,利用分子生物学方法,对Hn-UK融合蛋白进行了分子改造,包括置换连接肽,改变两个半分子(moiety)的相对位置,以及对连接肽附近明确的蛋白酶位点进行突变等方法,并分别研究了改造后的11种Ⅱn-1inker-UK或UK-linker-Ⅱn突变体在CHO细胞中分泌性表达时的稳定性,最终筛选到一种抗降解的突变体.     

人源化鼠抗人纤维蛋白单链抗体-尿激酶融合蛋白在大肠杆菌中的功能性表达

尿激酶是目前临床上广泛使用的一种有效的溶栓制剂 ,但由于尿激酶缺乏对血栓的特异亲和性 ,导致临床上尿激酶的使用剂量较大 ,容易出现全身性出血等副作用。因而开发对血栓特异的导向溶栓制剂是目前溶栓药研制的一个重要方向。本实验室在以前的工作中 ,利用噬菌体表面呈现技术 ,筛选到一种对人纤维蛋白特异的鼠单链抗体[1 ] ,在对该鼠抗体可变区进行结构模建的基础上[2 ] ,对其进行了人源化改造和体外亲和力成熟 ,得到亲和力和特异性较鼠抗体更好的人源化单链抗体[3 ] 。为研制导向溶栓制剂 ,本实验室构建了人源化单链抗体 低分子量尿激酶的…     

Purification of fusion proteins expressed by pEX3 and a truncated pEX3 derivative

A derivative of the pEX3 expression vector was constructed that codes for the first 407 amino acids of the 1051 amino acids of the pEX3 fusion protein. The amount of truncated fusion protein (40 mg/g cells), obtained by expression in E. coli, was similar to that produced by the original pEX3 vector. The truncated fusion protein was purified more easily from E. coli contaminants than the original fusion protein by washing with 2 M urea and 0.5% Triton X-100.     

PTD-NPY融合基因的克隆及其在毕赤酵母中的分泌表达

应用重叠延伸PCR方法扩增HIV-1 TAT蛋白转导结构域(PTD)与鼠源神经肽Y(NPY)的融合基因,克隆目的片段并插入酵母表达载体pPICZαA,构建成重组表达质粒pPICZα-PTD-NPY.PCR和酶切鉴定及测序正确后,经限制性内切酶Sac Ⅰ线性化重组表达质粒并通过电转化整合到巴斯德毕赤酵母菌GS115的染色体基因组中.阳性重组酵母菌用含1%甲醇的培养基诱导其分泌表达.经过120 h的诱导,取上清浓缩除盐后进行SDS-PAGE电泳,表明该系统成功表达了PTD-NPY融合蛋白,Western blotting实验证实表达产物具有特异性.获得真核表达的PTD-NPY融合蛋白,为下一步的应用研究提供了物质基础.     

Expression of a connexin 43/beta-galactosidase fusion protein inhibits gap junctional communication in NIH3T3 cells

Gap junctions contain membrane channels that mediate the cell-to-cell movement of ions, metabolites and cell signaling molecules. As gap junctions are comprised of a hexameric array of connexin polypeptides, the expression of a mutant connexin polypeptide may exert a dominant negative effect on gap junctional communication. To examine this possibility, we constructed a connexin 43 (Cx43)/beta-galactosidase (beta-gal) expression vector in which the bacterial beta-gal protein is fused in frame to the carboxy terminus of Cx43. This vector was transfected into NIH3T3 cells, a cell line which is well coupled via gap junctions and expresses high levels of Cx43. Transfectant clones were shown to express the fusion protein by northern and western analysis. X-Gal staining further revealed that all of the fusion protein containing cells also expressed beta-gal enzymatic activity. Double immunostaining with a beta-gal and Cx43 antibody demonstrated that the fusion protein is immunolocalized to the perinuclear region of the cytoplasm and also as punctate spots at regions of cell-cell contact. This pattern is similar to that of Cx43 in the parental 3T3 cells, except that in the fusion protein expressing cells, Cx43 expression was reduced at regions of cell-cell contact. Examination of gap junctional communication (GJC) with dye injection studies further showed that dye coupling was inhibited in the fusion protein expressing cells, with the largest reduction in coupling found in a clone exhibiting little Cx43 localization at regions of cell-cell contact. When the fusion protein expression vector was transfected into the communication poor C6 cell line, abundant fusion protein expression was observed, but unlike the transfected NIH3T3 cells, no fusion protein was detected at the cell surface. Nevertheless, dye coupling was inhibited in these C6 cells. Based on these observations, we propose that the fusion protein may inhibit GJC by sequestering the Cx43 protein intracellularly. Overall, these results demonstrate that the Cx43/beta-gal fusion protein can exert a dominant negative effect on GJC in two different cell types, and suggests that it may serve as a useful approach for probing the biological function of gap junctions.     

Functional expression of an earthworm fibrinolytic enzyme in <Emphasis Type="Italic">Escherichia coli</Emphasis>

Two cDNA fragments (lrF1 and lrF2) representing a fibrinolytic enzyme gene of F-III-2 (GenBank AB045719), without and with signal peptide coding sequence, were cloned from earthworm Lumbricus rubellus. The two fragments were inserted into bacterial expression vector pET28a (+), respectively. Subsequent expression showed that both lrF1 and lrF2 proteins were produced as an inclusion body form in E. coli BL21 (DE3) pLysE. After protein refolding and purification, the fusion lrF1 and its derivative without poly histidine tags at the N-terminus showed fibrinolytic activity on fibrin plates with relative activity of 134.3 U/mg protein and 139.7 U/mg protein, respectively, whereas the fusion lrF2 and its derivative without the tags at the N-terminus, had no fibrinolytic activity. The results indicated that the E. coli expression system could not recognize the endogenous signal peptide of F-III-2, and the effect of the histidine tags at the N-terminus on the fibrinolytic activity of the expressed protein was insignificant.     

Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase

A recombinant chimeric plasminogen activator (f beta/scuPA-32k), with a fibrin beta-chain peptide (comprising Gly15 through Arg 42) linked to the N-terminal of a low molecular mass (32 kDa) single-chain urokinase (scuPA-32k, comprising Leu144 through Leu 411) via a 50 amino acid linker sequence, was produced by expression the corresponding chimeric cDNA in Escherichia coli cells. After refolding in vitro, the chimeric protein was purified to homogeneity by zinc chelate-Sepharose chromatography, Sephacryl S200 chromatography and benzamidine-Sepharose chromatography in sequence. The apparent molecular mass was 36 kDa shown by SDS-PAGE analysis. The special activity was 87,000 IU/mg detected by fibrin plate determination. F beta/scuPA-32k could directly activate plasminogen following Michaelis-Menten kinetics with K(m) = 0.52 microM and k(2) = 0.0024 s(-1). Mediated by plasmin, the single-chain molecule could be converted to the active two-chain molecule. The chimeric protein had 3.3 times higher fibrin affinity than scuPA-32k in the fibrin concentration of 3.2 mg/mL, while the chimeric protein inhibited the fibrin clotting and platelet aggregation. F beta/scuPA-32k showed a higher thrombolytic potency in vitro plasma clot lysis than scuPA-32k and depleted less fibrinogen in plasma. These results showed that the chimeric protein had not only higher fibrinolytic activity but also anti-thrombus activity. Further evaluation of the thrombolytic potential in appropriate animal models is required.     

Controlled Growth of Chinese Hamster Ovary Cells and High Expression of Antibody-IL-2 Fusion Proteins by Temperature Manipulation

Growth and the expression of the anti-ErbB2 scFv-Fc-IL2 fusion protein in Chinese hamster ovary (CHO) cells were in association at 37 degrees C. The expression of the fusion protein was no more than 25 microg/ml. At 30 degrees C the cell growth was arrested but the cells continued to produce the fusion protein up to 60-80 microg/ml. About 50% of CHO cells were rapidly blocked in G2/M phase after the temperature was shifted from 37 to 30 degrees C. Lowering temperature resulted in cell growth arrest, but maintained cell viability for a longer time and enhanced the production of the antibody-IL-2 fusion protein in CHO cells.     

流行性感冒病毒M2蛋白可溶性表达及其免疫原性的研究

流行性感冒（流感）的M2蛋白是其保护性抗原之一,在几科所有甲型流感病毒中高度保守,因此可以用来研究具有交叉保护能力的流感疫苗。然而M2分子在病毒颗粒中含量非常少,用从病毒中纯化的方法很难获得足够的免疫原。在原核表达时发现,M2蛋白对宿主菌具有很强的毒性作用,导至其死亡,因此很难获得高表达。在本研究中,采用RT－PCR方法从病毒感染的MDCK细胞中克隆了A1／PR／8／34毒株的M2基因,然后通过基因工程手段缺失了M2蛋白的跨膜区26－55位氨基酸的编码序列,将其克隆以pET-32a中,与硫氧还蛋白融合,在大肠杆菌中获得了高效表达,并且表达产物以可溶形式存在,不形成包涵体。利用硫酸铵盐析结合金属离子鏊和柱亲和层析的方法纯化了表达的融合蛋白。免疫荧光实验表明,融合蛋白免疫小鼠后产生的抗血清能够与流感病毒感染的细胞发生特异性的结合,证明表达产物具有流感病毒M2蛋白的抗原性。